Click here to stream the public defence
Due to copyright issues, an electronic copy of the thesis must be ordered from the faculty. For the faculty to have time to process the order, the order must be received by the faculty at the latest 2 days before the public defence. Orders received later than 2 days before the defence will not be processed. After the public defence, please address any inquiries regarding the thesis to the candidate.
Trial Lecture – time and place
See Trial Lecture.
Adjudication committee
- First opponent: Associate professor Heli Harvala Simmonds, NHS Blood and Transplant, UK
- Second opponent: Professor Christine Rinaldo Hanssen, The Arctic University of Norway,
- Third member and chair of the evaluation committee: Professor Lars Eide, University of Oslo
Chair of the Defence
Professor Olav Dalgard, University of Oslo
Principal Supervisor
Associate Professor Susanne G. Dudman, University of Oslo
Summary
Hepatitis E virus (HEV) is one of the main causes of acute hepatitis globally. In the thesis Hepatitis E Virus Epidemiology and Vaccine Response: Studies from Norway and Bangladesh, Joakim Øverbø and his collaborators addresses research questions concerning the prevalence, transmission, and prevention of HEV across different income regions. Historically HEV has been recognized as a significant health concern in low-income countries, especially dangerous to pregnant women and their offspring, with no approved vaccine or treatment to protect them. Recently, it has become apparent that other genotypes of HEV are prevalent in many high- and middle-income countries, but the situation in Norway was unknown.
The first study within the thesis aimed to ascertain the prevalence of past HEV infection (seroprevalence) among different groups of people and swine in Norway. It revealed a seroprevalence of 14% in Norwegian blood donors, increasing to 20-30% in individuals with occupations involving direct swine contact, and reaching 73% in swine populations.
The second study was conducted in rural Bangladesh, assessing the safety and immunogenicity of a novel HEV vaccine (HEV 239). 100 individuals from two villages received either HEV 239 or a hepatitis B vaccine as a control. The results showed that the HEV 239 vaccination regimen was safe and elicited a strong and likely functional immune response against HEV.
The last study evaluates the use of dried blood spots (DBS) for HEV IgG detection as an easy, cheaper, less invasive, and more robust alternative to conventional serum or plasma samples. The method was found to be both reliable and accurate for many areas of research.
The findings underscore the necessity of incorporating HEV into the primary diagnostic considerations for acute hepatitis cases in Norway. Furthermore, the results advocate for larger trials of the HEV 239 vaccine, particularly in high-risk groups in South-East Asia and Africa. DBS presents a methodological advancement in serological HEV research, especially beneficial in these regions.
Additional information
Contact the research support staff.